NCT04708587 Appropriate Duration of Anti-Platelet straTegy in Patients With Advance Chronic Kidney Disease After New Generation Drug Eluting Stents (ADAPT-CKD)
| NCT ID | NCT04708587 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yonsei University |
| Condition | Chronic Kidney Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 900 participants |
| Start Date | 2021-03-23 |
| Primary Completion | 2027-03-13 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 900 participants in total. It began in 2021-03-23 with a primary completion date of 2027-03-13.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this prospective randomized clinical trial is to compare the clinical outcomes according to the duration of aspirin and clopidogrel or prasugrel with dual anti-platelet therapy after percutaneous coronary intervention in patients with advanced chronic kidney disease using a new generation drug eluting stents.
Eligibility Criteria
Inclusion Criteria: 1. Over 19 years old 2. Chronic Renal Failure Stage IIIb, IV, V (CKD-EPI eGFR \<45 / \<30 / \<15 or dialysis) 3. Patients treated with a new generation drug eluting stent. 4. Patients who signed consent form Exclusion Criteria: 1. Over 85 years old 2. Patients with high risk of bleeding 1) History of hemorrhagic stroke 2) Stroke, dementia or central nervous system damage within 1 year 3) Head trauma or brain surgery within 6 months 4) Tumor in the skull 5) If aortic dissection is suspected 6) Internal bleeding within 6 weeks 7) In case of active bleeding or bleeding disorder 8) In case of major surgery, trauma or bleeding within 3 weeks 3. Patients who need oral anticoagulant 4. Pregnant women or women of childbearing age 5. Life expectancy is less than 1 year 6. Patients with a history of intracranial bleeding 7. Moderate to severe hepatic impairment (Child-Pugh class B or C)
Contact & Investigator
Jung-Sun Kim, MD, PhD, FESC
PRINCIPAL INVESTIGATOR
Severance Hospital
Frequently Asked Questions
Who can join the NCT04708587 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, up to 84 Years, studying Chronic Kidney Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04708587 currently recruiting?
Yes, NCT04708587 is actively recruiting participants. Contact the research team at KJS1218@yuhs.ac for enrollment information.
Where is the NCT04708587 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT04708587 clinical trial?
NCT04708587 is sponsored by Yonsei University. The principal investigator is Jung-Sun Kim, MD, PhD, FESC at Severance Hospital. The trial plans to enroll 900 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.